With pressure from its biggest shareholder to sell, Swiss biotech Actelion (ALOIF.PK) may see a...

|By:, SA News Editor

With pressure from its biggest shareholder to sell, Swiss biotech Actelion (ALOIF.PK) may see a battle for its future like the one for Genzyme (GENZ) - with the same deal-closing mechanism, a contingent value right. Actelion's success hinges on key heart and lung drug trials in the coming year.